TRIM65 and hepatocellular carcinoma: Nucleotide synthesis inhibitors have already been available as antineoplastic agents for cancer therapy and several enzymes relevant to pyrimidine metabolism are clinically approved as treatment options.[8] Here, we found that TRIM65 could up‐regulate numerous metabolites in the uracil pathway, which served as nucleotides and as an energy source for cellular metabolism, promoting the rapid proliferation of HCC cells.